Trial Profile
Phase 1/2a Study of 2-Hydroxypropyl-Beta-Cyclodextrin Therapy for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Adrabetadex (Primary)
- Indications Niemann-Pick disease type C
- Focus Biomarker; Therapeutic Use
- 27 Oct 2023 Status changed from active, no longer recruiting to recruiting.
- 29 Jun 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 29 Jun 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.